CTIS2023-510240-20-00招募中1 期
Combination of Ponatinib Plus Chemotherapy As Frontline Treatment For Patients With BCR/ABL1-Like Acute Lymphoblastic Leukemia (BCR/ABL1-Like ALL) - BALLik. ALL2922 - GIMEMA ALL2922
Fondazione Gimema Franco Mandelli Onlus0 个研究点目标入组 32 人开始时间: 2024年6月27日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- •Age18-65 years., De novo Ph+-like ALL, as defined by the BCR/ABL1-like predictor (13)., WHO score =2, Adequate liver function, as defined by the following criteria: total serum bilirubin =1.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome, alanine aminotransferase (ALT) =2.5 ×ULN or aspartate aminotransferase (AST) =2.5 x ULN or leukemia related., Adequate pancreatic function as defined by serum lipase and amylase =1.5 × ULN or leukemia related, No history of dyslipidemia, thrombotic events or cardiac disease., For females of childbearing potential, a negative pregnancy test must be documented. Female and male patients who are fertile must agree to use an effective form of contraception with their sexual partners from enrollment through 12 months after the end of treatment., Signed informed consent, according to ICH/EU/GCP and national regulation.
排除标准
- •WHO performance status >2., Uncontrolled hypertension (diastolic blood pressure >90 mm Hg; systolic >140 mm Hg). Patients with hypertension should be under treatment on study entry to effect blood pressure control., Taking medications that are known to be associated with torsades de pointes, Gastrointestinal (GI) function impairment, or a GI disease that may significantly alter the absorption of study drugs., Patients who are currently receiving treatment with any of the medications with potential to prolong QT interval (listed in Appendix F) if the medications cannot be either discontinued or switched to a different medication prior to starting study drug, Patients who have received any investigational drug = 4 weeks., Patients who have undergone major surgery = 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy, Patients who are pregnant or breast feeding and adults of reproductive potential not employing an effective method of birth control (women of childbearing potential must have a negative serum pregnancy test within 48 hrs. prior to administration of Ponatinib). Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients must agree to employ two effective reliable methods of birth control throughout the study and for up to 12 months following discontinuation of study drugs, Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention, Patients unwilling or unable to comply with the protocol, Taking any medications or herbal supplements that are known to be strong inhibitors of CYP3A4 within at least 14 days before the first dose of ponatinib., Creatinine levels > 2.5mg/dl or glomerular filtration rate (GFR) < 20 ml/min or proteinuria >3.5 g/day., Active HBV or HCV hepatitis, or AST/ALT > 2.5 x ULN and bilirubin > 1.5 x ULN., History of acute pancreatitis within 1 year of study or history of chronic pancreatitis., History of alcohol abuse, Ongoing or active infections, Uncontrolled hypertriglyceridemia (triglycerides >450 mg/dL)., Clinically significant, uncontrolled or active cardiovascular disease, specifically including, but not restricted to: - Any history of myocardial infarction, stroke, or revascularization, unstable angina or transient ischemic attack within 6 months prior to enrollment, - Congestive heart failure within 6 months prior to enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of normal per local institutional standards, - History of clinically significant (as determined by the treating physician) atrial arrhythmia, - Any history of ventricular arrhythmia, - Any history of venous thromboembolism including deep venous thrombosis or pulmonary embolism.
研究者
相似试验
进行中（未招募）
1 期
The effectivness and safety of ponatinib administered in combination with reduced chemotherapy in treatment of acute lymphoblastic leukemia in adults.EWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIAMedDRA version: 21.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864EUCTR2019-004540-29-CZÚstav hematologie a krevní transfuze32
招募中
2 期
Combining Afatinib and concurrent chemotherapy, followed by Osimertinib and concurrent chemotherapy, in untreated EGFR positive NSCLC tumorsNSCLClung cancerNL-OMON52389Vrije Universiteit Medisch Centrum21
招募中
不适用
Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumorson small cell lung cancerNL-OMON28617Amsterdam UMC21
终止
不适用
Combination chemotherapy with pazopanib and ICE in children and adolescents with relapsed/refractory solid tumorsNeoplasmsKCT0003260Samsung Medical Center46
未知
1 期
Clinical evaluation of NK211 and CDDP for cervical cancer.Advanced and/or recurrent cervical cancer.JPRN-jRCT2080221794ippon Kayaku Co., Ltd.